IRADIMED CORPIRMD
ASignal's systematic analysis rates IRMD as Neutral.
Reflects the latest available analysis · analyzed Sep 19, 2026
The case on IRMD
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin of 75.86% indicating pricing power
- Exceptional return on equity at 23.52%
- Debt-free balance sheet with $59.08M in cash
- High current and quick ratios suggesting strong liquidity
- RSI at 24.4 indicates potential oversold condition
- Negative price momentum and MACD below signal line
- Declining earnings growth (YoY: -9.3%)
- Low revenue growth at 0.30% YoY
- High valuation metrics: P/E of 45.88x and P/S of 12.16x
- No Reddit mentions, indicating low retail investor interest
See the full verdict on IRMD
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes IRMD
Most investors never get a second opinion, let alone several. ASignal runs IRMD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.